Vigabatrin

Vigabatrin
Clinical data
Pronunciation	/vaɪˈɡæbətrɪn/; vy-GAB-ə-trin
Trade names	Vigafyde, Sabril, others
Other names	γ-Vinyl-GABA
AHFS/Drugs.com	Monograph
MedlinePlus	a610016
License data	US DailyMed: Vigabatrin;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	N03AG04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	80–90%
Protein binding	0%
Metabolism	not metabolized
Elimination half-life	5–8 hours in young adults, 12–13 hours in the elderly.
Excretion	Kidney
Identifiers
	IUPAC name (RS)-4-aminohex-5-enoic acid;
CAS Number	68506-86-5 ;
PubChem CID	5665;
IUPHAR/BPS	4821;
DrugBank	DB01080 ;
ChemSpider	5463 ;
UNII	GR120KRT6K;
KEGG	D00535 ;
ChEMBL	ChEMBL89598 ;
CompTox Dashboard (EPA)	DTXSID4041153 ;
ECHA InfoCard	100.165.122
Chemical and physical data
Formula	C6H11NO2
Molar mass	129.159 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	171 to 177 °C (340 to 351 °F)
	SMILES O=C(O)CCC(\C=C)N;
	InChI InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9) ; Key:PJDFLNIOAUIZSL-UHFFFAOYSA-N ;
	(verify)

Vigabatrin, sold under the brand name Vigafyde among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures.

It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.^[7]

Vigabatrin is generally used only in cases of treatment-resistant epilepsy due to the risk of permanent vision loss.^[8] Although estimates of visual field loss vary substantially, risk appears to be lower among infants with treatment duration less than 12 months and the risk of clinically meaningful vision loss is very low among children treated for infantile spasms.^[9]^[10]

^ Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
^ "Sabril- vigabatrin tablet, film coated". DailyMed. October 20, 2021. Retrieved September 5, 2024.
^ "Sabril- vigabatrin powder, for solution". DailyMed. October 20, 2021. Retrieved September 5, 2024.
^ "Vigafyde- vigabatrin solution". DailyMed. August 23, 2024. Retrieved September 5, 2024.
^ "Vigadrone- vigabatrin tablet". DailyMed. July 14, 2023. Retrieved September 5, 2024.
^ "Vigpoder- vigabatrin powder, for solution". DailyMed. March 20, 2024. Retrieved September 5, 2024.
^ Long PW (2003). "Vigabatrin". Drug Monograph. Internet Mental Health. Archived from the original on April 23, 2006.
^ "Sabril (vigabatrin) Tablets for Oral Use, Powder for Oral Solution. Full Prescribing Information" (PDF). Lundbeck.
^ Hussain SA, Schmid E, Peters JM, Goyal M, Bebin EM, Northrup H, et al. (Tuberous Sclerosis Complex Autism Center of Excellence Network) (2018). "High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex". Epilepsy Research. 148: 1–7. doi:10.1016/j.eplepsyres.2018.09.016. PMC 6347124. PMID 30296632.
^ Schwarz MD, Li M, Tsao J, Zhou R, Wu YW, Sankar R, et al. (2016). "A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience". Epilepsy & Behavior. 57 (Pt A): 29–33. doi:10.1016/j.yebeh.2016.01.012. PMID 26921595.

[1] Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.

[2] "Sabril- vigabatrin tablet, film coated". DailyMed. October 20, 2021. Retrieved September 5, 2024.

[3] "Sabril- vigabatrin powder, for solution". DailyMed. October 20, 2021. Retrieved September 5, 2024.

[Vigafyde_FDA_label-4] "Vigafyde- vigabatrin solution". DailyMed. August 23, 2024. Retrieved September 5, 2024.

[5] "Vigadrone- vigabatrin tablet". DailyMed. July 14, 2023. Retrieved September 5, 2024.

[Vigpoder_FDA_label-6] "Vigpoder- vigabatrin powder, for solution". DailyMed. March 20, 2024. Retrieved September 5, 2024.

[what_is_vigabatrin-7] Long PW (2003). "Vigabatrin". Drug Monograph. Internet Mental Health. Archived from the original on April 23, 2006.

[8] "Sabril (vigabatrin) Tablets for Oral Use, Powder for Oral Solution. Full Prescribing Information" (PDF). Lundbeck.

[9] Hussain SA, Schmid E, Peters JM, Goyal M, Bebin EM, Northrup H, et al. (Tuberous Sclerosis Complex Autism Center of Excellence Network) (2018). "High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex". Epilepsy Research. 148: 1–7. doi:10.1016/j.eplepsyres.2018.09.016. PMC 6347124. PMID 30296632.

[10] Schwarz MD, Li M, Tsao J, Zhou R, Wu YW, Sankar R, et al. (2016). "A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience". Epilepsy & Behavior. 57 (Pt A): 29–33. doi:10.1016/j.yebeh.2016.01.012. PMID 26921595.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]